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Treating the placenta to prevent 
adverse effects of gestational 
hypoxia on fetal brain development
Tom J. Phillips1, Hannah Scott  1, David A. Menassa1, Ashleigh L. Bignell1, Aman Sood1, Jude 
S. Morton2, Takami Akagi3,4, Koki Azuma3, Mark F. Rogers5, Catherine E. Gilmore1, Gareth 
J. Inman6, Simon Grant7, Yealin Chung8, Mais M. Aljunaidy2, Christy-Lynn Cooke2, Bruno R. 
Steinkraus9, Andrew Pocklington  10, Angela Logan11, Gavin P. Collett12, Helena Kemp13, 
Peter A. Holmans10, Michael P. Murphy11, Tudor A. Fulga9, Andrew M. Coney14, Mitsuru 
Akashi3,4, Sandra T. Davidge2,15 & C. Patrick Case1
Some neuropsychiatric disease, including schizophrenia, may originate during prenatal development, 
following periods of gestational hypoxia and placental oxidative stress. Here we investigated if 
gestational hypoxia promotes damaging secretions from the placenta that affect fetal development 
and whether a mitochondria-targeted antioxidant MitoQ might prevent this. Gestational hypoxia 
caused low birth-weight and changes in young adult offspring brain, mimicking those in human 
neuropsychiatric disease. Exposure of cultured neurons to fetal plasma or to secretions from the 
placenta or from model trophoblast barriers that had been exposed to altered oxygenation caused 
similar morphological changes. The secretions and plasma contained altered microRNAs whose targets 
were linked with changes in gene expression in the fetal brain and with human schizophrenia loci. 
Molecular and morphological changes in vivo and in vitro were prevented by a single dose of MitoQ 
bound to nanoparticles, which were shown to localise and prevent oxidative stress in the placenta 
but not in the fetus. We suggest the possibility of developing preventative treatments that target the 
placenta and not the fetus to reduce risk of psychiatric disease in later life.
The hypothesis for the fetal origin of adult diseases was first proposed in 1990 by David Barker1. Since then, 
evidence has accumulated lending credence to the hypothesis that some neuropsychiatric diseases that become 
symptomatic during adolescence or in adulthood have a neurodevelopmental origin2, 3. Furthermore, psycho-
logical disorders such as schizophrenia, attention deficit hyperactivity disorder and autism have been associated 
with episodes of altered oxygen during pregnancy, as early as the end of the first trimester3–7. For schizophrenia in 
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particular, a two-hit hypothesis has been proposed where the first ‘hit’ occurs in utero, disrupting neuroanatomi-
cal wiring and thereby increasing susceptibility to a second hit in later life, which triggers the disease symptoms8.
The neuropathology of neuropsychiatric disorders has been studied extensively and pathological findings 
generally overlap between the various disorders. For example, dendrite dysgenesis9, 10 and dendritic spine pathol-
ogy11–16 of cortical neurons has been often reported in multiple brain regions including temporal, frontal and 
occipital cortices from autism, schizophrenia and mental retardation patients. Changes in the catecholamine 
system including altered tyrosine hydroxylase activity17, 18, loss of parvalbumin-positive neurons19, 20, and dys-
function of NMDA receptors9, 17, 21, 22 have been observed in post-mortem brains of patients with schizophrenia 
and autism spectrum disorders as well as in animal models. Finally, abnormal astrocyte number or function has 
also been proposed as a critical change in autism and schizophrenia brains23–26.
The mechanisms by which adverse events during gestation can alter fetal development are not well under-
stood. The placenta, which presents a double-layered interface between maternal and fetal blood during the 
first trimester, may play an important role21, 27–32. During very early development the fetal brain’s supply of the 
transmitter serotonin33, and possibly others34, is derived from the placenta. Obstetric challenge in the form of 
maternal inflammation, can alter this signalling from the placenta to the brain and disrupt axonal outgrowth of 
5HT-positive neurons within the fetal forebrain35. Furthermore preeclampsia, a pregnancy complication associ-
ated with placental insufficiency and abnormal oxygenation of the placenta, is a risk factor for the development 
of neuropsychiatric disease36–39.
We have shown previously that induction of oxidative stress in the human placenta or a simple model of it, a 
trophoblast cell barrier, causes it to release molecules that elicit DNA damage in human fibroblasts and human 
embryonic stem cells40–42. Secretions from barriers exposed to hypoxia also caused morphological, electrophysio-
logical and receptor-related changes to embryonic neurones and astrocytes, both in culture and in the developing 
brain in vivo43. We noted that soluble drugs such as MitoQ, a mitochondrial antioxidant, Gap26, which blocks 
connexin hemichannels and gap junctions, PPADS, a purinergic receptor antagonist, and C17, an antagonist of 
pannexin channels, could inhibit intercellular signalling between the layers of the barrier and prevent the secre-
tion of DNA damaging factors from the barrier40, 41. These observations suggest that secreted placental factors 
may be candidate effectors for fetal programming of disease. They present an opportunity to treat the placenta via 
the mother to prevent harmful signalling to the fetus.
Few drugs are used in pregnancy because of their potential adverse effects on the fetus, should they pass 
through the placenta. Previously we showed that nanoparticles accumulate in the top layer of a bilayered troph-
oblast barrier and do not pass through it41, 42. Coupling a drug that stops oxidative stress in the placenta to nano-
particles could therefore prevent passage of the drug through the placenta and to the fetus. Here we investigate the 
potential of treating the placenta with a nanoparticle-bound MitoQ prior to a hypoxic insult to prevent damaging 
signalling that could affect neurodevelopment in a rat model of gestational hypoxia in vivo.
Results
Antioxidant MitoQ was successfully coupled to nanoparticles (NPs) (Supplementary Data; Supplementary 
Fig. S1) and tested in vitro on bilayered barriers of BeWo cells41, a choriocarcinoma cell line. MitoQ-NPs were 
most effective at reducing the effects of in vitro hypoxia, compared to NP-bound Gap26 or PPADS (Supplementary 
Fig. S2). When NPs were applied to BeWo barriers for up to 24 h, they were predominantly located in the top layer 
of the barrier (Fig. 1a)40. There was no evidence of passage of NPs, or release of MitoQ, across the barriers into the 
media below except at a very high NP dose (2 mg/ml) (Fig. 1c; Supplementary Table S1). For subsequent in vivo 
experiments a 2580-fold lower dose was selected, at which NPs were not observed to cross the in vitro barrier.
We investigated if treatment with MitoQ-NPs would be able to prevent placental oxidative stress, altered 
signalling from the placenta and neuroanatomical changes in the offspring in an established in vivo model of 
gestational hypoxia44. Briefly, pregnant rats were exposed to 11% oxygen for the last 6 days of pregnancy. This 
exposure reduces birth-weight and is known to cause abnormal fetal cardiovascular programming30, 45. We used 
a single dose of MitoQ-NPs, injected intravenously into the dam at the start of the hypoxic exposure, as the least 
invasive procedure.
Effects of MitoQ-NPs on placenta and fetus. As expected30, 45, birth-weights were decreased follow-
ing maternal hypoxia (Fig. 2a). Maternal MitoQ-NP injection rescued over 60% of this deficit. Hypoxia and 
MitoQ-NPs had no effect on body weight at P30, placental weight or brain weight (Fig. 2a; Supplementary 
Fig. S3).
We investigated if NPs could reach the placenta in vivo and whether maternal hypoxia or MitoQ-NP injection 
caused changes to the placenta. NPs were detected within the placenta, most prevalently in the labyrinth but also 
in the junctional zone (Fig. 2b). The NPs were particularly found in cytotrophoblasts, which face the maternal 
circulation, and less commonly seen in syncytiotrophoblast cells, which face the fetus. NPs were not found in the 
fetal brain or in thoracic or abdominal tissues including liver (Fig. 2b). NPs were detected in the maternal liver, 
particularly in Kupffer cells and hepatocytes (Supplementary Fig. S3). Areas of NP localisation were observed 
sparsely throughout the maternal brain. Within these areas, fluorescence was mainly detected within neuronal 
processes (Supplementary Fig. S3).
Neither maternal hypoxia nor NP injection caused a change in placental fine structure (Fig. 2c) or in the width 
of labyrinth or decidua (Supplementary Fig. S3). Nor was the fetal capillary network altered in the labyrinth 
(Fig. 2d; Supplementary Fig. S3). Levels of oxidative stress were significantly increased in the labyrinth and junc-
tional zones of the placenta following gestational hypoxia. Treatment with MitoQ-NPs significantly reduced levels 
of oxidative stress (Fig. 2e; Supplementary Fig. S3). Analysis of maternal liver and fetal liver showed elevated 
levels of oxidative stress following maternal hypoxia. After MitoQ treatment increased oxidative stress was still 
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observed in fetal liver but not in maternal liver (Fig. 2e). No changes in oxidative stress were detected in the fetal 
brain after maternal hypoxia or NP treatment (Fig. 2e; Supplementary Fig. S3).
These observations suggest that the NPs injected into the maternal circulation reduce oxidative stress in 
maternal tissues and placenta but not in fetal tissues following gestational hypoxia. Moreover, they rescue fetal 
birth-weight although they do not reach the fetus.
Effects of MitoQ-NPs on placental secretions. Several authors have stressed the importance of the 
placenta, as the interface between mother and fetus, in fetal programming21, 27–32. We hypothesised that secretions 
from the placental barrier in response to hypoxia, as observed previously in vitro43, might play a role in fetal devel-
opment in vivo. By targeting oxidative stress in the placenta, MitoQ-NPs may prevent potentially damaging sig-
nalling from the placenta. We tested the hypothesis that MitoQ-NPs could alter the secretion of molecules from 
the placenta by investigating microRNAs (miRNAs), proteins including bone morphogenetic proteins (BMPs) 
and amino acids, all of which have potential relevance to fetal development46–49, psychiatric diseases50–52 and pla-
cental hypoxia53, 54. Levels of these molecules were measured in fetal plasma and in culture medium conditioned 
ex vivo by placental tissue (‘rat placenta conditioned medium’), collected from rats exposed to gestational hypoxia 
and MitoQ-NP treatment. Additionally, we analysed culture medium conditioned in vitro by bilayered barriers of 
BeWo cells (‘BeWo barrier conditioned medium’) following exposure to altered oxygen and MitoQ-NPs.
Changes to oxygen levels altered total levels of miRNAs, small RNAs and potentially small extracellular vesi-
cles, such as exosomes, released from BeWo barriers (Fig. 3a; Supplementary Fig. S4). There was no change in total 
miRNA or small RNA in medium conditioned by rat placenta after gestational hypoxia (Fig. 3b; Supplementary 
Fig. S4). However in media conditioned by BeWo barriers or rat placenta and in fetal plasma there was a complex 
pattern of increased and decreased levels of individual miRNA (Fig. 3c–e; Supplementary Fig. S4). The applica-
tion of MitoQ-NPs partially prevented these changes for the majority of differentially secreted miRNAs.
The pattern of secretion of BMPs from BeWo barriers was also altered following exposure to reduced oxygen 
(Fig. 3f). This was prevented by the MitoQ-NPs. The proteome profile of fetal plasma was changed in response 
to gestational hypoxia (Fig. 3h,j). Proteins with altered abundance were significantly enriched for exosomes and 
lipoproteins (Fig. 3k,l). No change in protein abundance was seen in the fetal plasma after maternal MitoQ-NP 
treatment (Fig. 3h,j). In contrast, in rat placenta conditioned media, there was little change in protein levels after 
gestational hypoxia but significant change after MitoQ-NP treatment (Fig. 3g,i).
Levels of amino acids in rat placenta conditioned media were not significantly altered in response to maternal 
hypoxia (Supplementary Tables S2–4; Supplementary Fig. S4).
Taken together these results indicate that gestational hypoxia selectively alters the secretion of miRNAs and 
proteins in vivo, ex vivo and in vitro. Maternal administration of MitoQ-NPs ‘normalises’ the miRNA secretion 
patterns in a global manner.
Effects of MitoQ-NPs on gene expression in the offspring brain. Having identified factors, such 
as miRNAs, which were differentially secreted from the placental barrier following a hypoxic insult, we wanted 
to investigate if these had the potential to play a role in shaping the brain during fetal development. miRNAs 
regulate mRNA abundance55 and have been shown to be involved in neurodevelopment and disease56. Moreover 
exosomes, extracellular vesicles known to carry miRNAs, can cross the blood-brain barrier and reach the brain57. 
Figure 1. Characterisation of MitoQ-NPs. (a) Confocal images of bilayered BeWo barriers 24 h after 
application of 2 mg/mL fluorescent NPs (green) to the top of the barrier. Tight junction protein ZO-1 is labelled 
in red, nuclei in blue. Scale bar = 10 μm. (b) Levels of fluorescence detected in the tissue culture medium below 
the bilayered BeWo barriers up to 24 h after application of different doses of NPs to the top of the barrier (n = 2). 
***p < 0.001 as determined by post-hoc testing following one-way ANOVA with Bonferroni correction for 
multiple comparisons.
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Using bioinformatics analyses we investigated the predicted target genes of those miRNAs that were differentially 
expressed in rat placenta conditioned media and in fetal plasma, in response to gestational hypoxia. The predicted 
target genes were enriched in the brain compared to other organs (p < 0.001) (Fig. 4a,d) as well as in biological 
processes linked to development (Fig. 4b,e). Furthermore, predicted miRNA targets were enriched within copy 
number variants (CNVs) found in schizophrenia cases compared to CNVs found in matched controls (Fig. 4c,f; 
Supplementary Table S5). An additional analysis conditioned on a minimal set of CNS-linked gene-sets previ-
ously shown to be enriched for schizophrenia CNVs in the same case-control data58; this indicated that while 
some of the enrichment seen in our predicted targets was shared with these known associated gene sets, a signif-
icant proportion seems to be independent (Supplementary Table S6). These results suggest that the differentially 
secreted miRNAs could target genes involved in neurodevelopment and neurodevelopmental disease.
Next we investigated if gene expression was altered in the fetal brain exposed to gestational hypoxia and if 
these changes may be correlated with the changes in secreted miRNAs. The mRNA levels of 510 genes were sig-
nificantly altered in the fetal brain after gestational hypoxia. Maternal MitoQ-NP administration reduced these 
effects (Fig. 4g). Genes down-regulated following hypoxia were enriched for developmental processes (Fig. 4h). 
Differentially expressed genes in the fetal brain were significantly enriched for predicted targets of those miR-
NAs that had been found to be significantly altered in fetal plasma and conditioned medium (Supplementary 
Table S7), suggesting a potential link between secreted miRNAs and cortical transcriptome changes following a 
hypoxic insult. For a subset of significant miRNAs, including miR-17-5p (Fig. 4i), negative correlation with one 
or more significant mRNA changes in the brain was detected (Table 1).
Figure 2. Effects of MitoQ-NPs on the rat in vivo. (a) Birth-weight (top left; n = 6 litters), placenta weight 
(top right; n = 6 litters) and body weight at P30 (bottom; n = 24 individuals) of offspring exposed to maternal 
normoxia, M(21%), or hypoxia, M(11%), preceded by maternal administration of saline or MitoQ-NPs. (b) 
Confocal images of rat placental labyrinth, fetal cortex and fetal liver at GD16 after maternal injection with 
saline or fluorescent NPs (green), counterstained with DAPI (blue), scale bar = 100 μm. (c) Light micrographs 
showing the gross histology (H&E stain) of the placental labyrinth at GD20 following in vivo normoxia or 
hypoxia with maternal saline or MitoQ-NP injection (scale bar = 2 μm). (d) Analysis of total area per field of 
view (top) and maximum diameter (bottom) of placental blood vessels after gestational hypoxia combined 
with maternal injection of saline or MitoQ-NPs (n = 3 placenta per condition, each from a different dam). (e) 
Levels of fluorescent dichlorofluorescein (DCF) as a measure of reactive oxygen species and thus oxidative 
stress in fetal brain (left, top) and liver (middle, top), maternal brain (left, bottom) and liver (middle, bottom) 
and placenta (right) after exposure to altered oxygen in vivo, with or without maternal MitoQ-NP injection 
(biological replicates: fetal and placental samples, n = 6; maternal samples, n = 3). Additional significant 
differences for ‘placenta’ graph: M(21%) + saline vs M(11%) + MitoQ-NP, p < 0.05; M(21%) + MitoQ-NP vs 
M(11%) + saline, p < 0.001. *p < 0.05, ***p < 0.001 as determined by post-hoc testing following ANOVA.
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Figure 3. Effects of MitoQ-NPs on secreted molecules from BeWo barriers and placenta and into fetal blood. 
Levels of molecules in media conditioned by bilayered BeWo barriers (a,c,f) or rat placenta (b,d,g,i), and in fetal 
plasma (e,h,j–l). BeWo barriers had been exposed to 21% oxygen, to 8% oxygen or to 2% oxygen followed by 8% 
oxygen to mimic hypoxia-reoxygenation (2–8%), with or without application of MitoQ-NPs. Placentas and fetal 
plasma were collected from rats exposed to gestational normoxia, M(21%), or hypoxia, M(11%), after maternal 
administration of saline or MitoQ-NPs. Placentas were incubated ex vivo for 24 h at 8% oxygen before collection 
of conditioned medium. (a,b) Total levels of small RNAs and miRNAs. (c–e) Log2-fold changes of miRNAs with 
significantly (p < 0.05) different secretion under altered oxygen alone (blue) or altered oxygen plus MitoQ-NP 
application (orange), relative to control levels (normoxia + saline). (f) Relative activity of BMPs in relative 
luminescence unit (RLU), normalised to 21%. Significant differences not shown in graph: BMP4, 21%vs2%, 
p = 0.01, 21%vs2-12%, p = 0.04; Other BMPs, 21%vs2%, p = 0.004; 21%vs2-12%, p = 0.04. (g,h) Levels of 
significant (p < 0.05) differentially abundant proteins in rat placenta conditioned medium (g) and fetal plasma 
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The results indicate that maternal MitoQ-NP treatment can partially prevent hypoxia-induced gene expres-
sion changes in the fetal brain and point towards a potential link between miRNAs secreted from the placenta and 
the transcriptome of the developing brain.
Neurodevelopmental effects of MitoQ-NPs in vitro and in vivo. The placenta may play an important 
role in the aetiology of neurodevelopmental disorders21, 30–32. Therefore, we further explored the potential link 
between placental secretions and changes in the offspring brain. We examined whether fetal plasma and media 
conditioned by BeWo barriers or rat placenta had similar biological effects on embryonic cortical neurons in cul-
ture. We further investigated if these effects might also be noted in vivo within the offspring brains at a later stage 
of development. We chose parameters that have relevance to psychological disorders9, 17, 24, 59.
In cortical cultures, exposure to conditioned media and plasma collected following a hypoxic episode caused a 
shortening of dendrites (Fig. 5a–c; Supplementary Fig. S5), a reduction of tyrosine hydroxylase (TH)-positive pro-
cess lengths (Fig. 5f,g; Supplementary Fig. S5), a loss of GluN1 receptor subunit staining (Fig. 5j–l; Supplementary 
Fig. S5) and an increase in astrocyte-to-neuron ratio (Fig. 5n–p; Supplementary Fig. S5). In general, such changes 
were also seen in the brain (Fig. 5d,m,q). A decrease in dendrite length was restricted to the thalamic reticular 
nucleus (TRN; Fig. 5d) although thick, abnormally branched dendrites were noted in the somatosensory cor-
tex (SSC; Fig. 5r). Process lengths of TH+ neurons were increased in cortex (CTX) and TRN (Fig. 5i), which 
contrasted with the reduction in process length observed after exposing cortical cultures to fetal plasma or rat 
placenta conditioned medium (Fig. 5f,g). However, the directionality of the effect observed in vivo was replicated 
when cortical cultures were exposed to BeWo conditioned medium (Fig. 5e) and when neuron-only cultures were 
exposed to media conditioned by rat placenta (Fig. 5h).
In general, the actions of MitoQ-NP treatment were also similar across the different models and either sig-
nificantly prevented the effects of hypoxia, or caused hypoxia to no longer have significant effects, on dendrite 
length (Fig. 5a–d; Supplementary Fig. S5), TH+ cell process length (Fig. 5e–i), GluN1 receptor subunit staining 
(Fig. 5j–m; Supplementary Fig. S5) and astrocyte-to-neuron ratio (Fig. 5n–q). Additionally, the numerical density 
of parvalbumin-containing cells was significantly reduced in TRN, CTX and SSC of offspring following mater-
nal hypoxia and rescued in the TRN by MitoQ-NP injection (Fig. 5s). Total cell count was not affected by either 
hypoxia or MitoQ-NP application in vitro or in the TRN, whereas a reduction in cell number was observed in the 
CTX (Supplementary Fig. S6). The number of TH+ cells were reduced in cortical cultures only after additional 
severe hypoxia was applied to the placenta ex vivo and no change was observed in vivo (Supplementary Fig. S6).
Recently it was demonstrated that lipopolysaccharide, which shows minimal transport across the blood-brain 
barrier, may nonetheless have toxic actions within the brain by acting on astrocytes located at the blood-brain bar-
rier60. We noted previously that glutamate may play a role in mediating the effects of hypoxia-conditioned media 
on cortical cultures43. We therefore tested the effects of media conditioned by rat placenta after maternal hypoxia 
on astrocyte signalling to neurons with and without glutamate blockade (Fig. 6). Dendrite lengths and GluN1 
staining intensity were decreased in mixed astrocyte/neuron cultures (Fig. 6a,g), unchanged in neuron-only 
cultures (Fig. 6b,h) and decreased if astrocyte cultures were first exposed and then this astrocyte-conditioned 
medium was applied to neuron-only cultures (Fig. 6c,i). Moreover these effects were blocked by the NMDA 
receptor antagonist MK-801. In contrast, TH+ cell processes, although decreased in mixed cultures (Fig. 6d) and 
after exposure to the astrocyte-conditioned media (Fig. 6f), were increased in neuron-only cultures, an effect that 
was not altered by the glutamate antagonist (Fig. 6e).
Together these results suggest that maternal administration of MitoQ-NPs can ameliorate some of the 
long-term effects of gestational hypoxia on the offspring brain. These effects can be replicated in cortical cultures 
via exposure to rat placenta conditioned media or fetal plasma and may involve astrocyte-to-neuron signalling, 
partially via glutamate.
Discussion
We showed that maternal injection of a single dose of NP-bound antioxidant MitoQ, during exposure to gesta-
tional hypoxia, reduced oxidative stress in the placenta and prevented a reduction of birth-weight (Supplementary 
Fig. S7). Birth-weight is a strong predictor for disease in later life61 and low birth-weight has been associated with 
altered neuropsychiatric outcomes2. Importantly the nanoparticle-bound drug appeared to exert its effect on the 
fetus indirectly, without passing through the placenta to the fetus. This is supported by the lack of nanoparticles 
detected in the fetus, the lack of MitoQ in conditioned media from BeWo barriers or rat placenta along with the 
(h). Differences were analysed between: normoxia + saline and hypoxia + saline (NSvHS); hypoxia + saline 
and hypoxia + MitoQ-NPs (HSvHM); normoxia + saline and hypoxia + MitoQ-NPs (NSvHM). (i) Log2-fold 
changes of proteins detected in rat placenta-conditioned medium under altered oxygen alone (blue) or altered 
oxygen plus MitoQ-NP application (orange), relative to control (normoxia + saline). Proteins depicted showed 
significant differential abundance in the hypoxia + MitoQ-NP conditioned compared to hypoxia + saline. 
n = 3 biological replicates, each from a different litter. (j) Log2-fold changes of proteins with significantly 
different abundance in fetal plasma under altered oxygen alone (blue) or altered oxygen plus MitoQ-NP 
application (orange), relative to control levels. n = 4 for groups normoxia + saline, normoxia + MitoQ-NPs 
and hypoxia + MitoQ-NPs; all others, n = 3. (k,l) Gene ontology analysis of significant differentially abundant 
proteins in fetal plasma after exposure to maternal hypoxia compared to normoxia. Enrichment of biological 
processes (k) and cellular compartments (l) is shown. Grey bars represent number of proteins assigned to each 
gene ontology term and black bars show respective p value. *p < 0.05, **p < 0.01, Tukey’s post-hoc test following 
one-way or two-way ANOVA.
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Figure 4. Characterisation of secreted miRNAs and transcriptome changes in the fetal brain. (a–f) Predicted 
targets of miRNAs that were significantly altered in response to maternal hypoxia in conditioned medium 
from rat placenta (a–c) or in fetal plasma (d–f) were analysed for enrichment of tissue types (a,d) and of 
biological processes (b,e). Predicted targets of all miRNAs, of upregulated miRNAs and of downregulated 
miRNAs were investigated for enrichment in CNVs associated with schizophrenia. Significant enrichment at 
p < 0.05 (grey line) shown in red (c,f). (g–i) Changes in the transcriptome were measured in the fetal cortex of 
offspring exposed to gestational normoxia or hypoxia and maternal administration of saline or MitoQ-NPs. 
Log2-fold changes of significant differentially expressed genes under hypoxia alone (blue) or hypoxia plus 
MitoQ-NP application (orange), relative to control levels (normoxia + saline) are shown (g). Significantly 
enriched biological processes of differentially expressed genes; the grey bars represent number of proteins 
assigned to each gene ontology term and the black bars show the respective p value (h). Correlation of miR-
17-5p abundance changes in fetal plasma with expression changes of the gene coding for Ribosome protein 
L10-like (RPL10L) in fetal brain, under Normoxia + Saline (NS) and Hypoxia + Saline (HS) conditions (i). Log-
transformed counts are shown. p value was adjusted for multiple comparisons using Benjamini-Hochberg.
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lack of effect of drug treatment on oxidative stress in the fetal liver or brain compared to maternal liver and the 
placenta. As large NPs (180 nm) were used, these observations correlate with previous findings that the passage 
of intravenously injected NPs across the placenta depends on their size62. MitoQ-NP treatment was also found 
to reduce oxidative stress in the placenta of control animals, which had not been exposed to hypoxia, as well as 
in maternal tissues. The lack of gross changes in the dams and control fetuses in response to maternal MitoQ-NP 
injection suggests that the treatment did not have adverse effects. However, a more detailed assessment is required 
to comprehensively investigate if MitoQ-NP administration could adversely, or beneficially, affect maternal health 
or fetal health in pregnancies without placental oxidative stress.
Furthermore, we observed that maternal MitoQ-NP treatment prevented some abnormal changes in neurons 
in response to gestational hypoxia. Shortening of dendrites and a reduction in the density of immunostaining 
of NMDA receptor subunit GluN1 were detected in response to hypoxia. Similar types of change have been 
reported in neuropsychiatric disease such as schizophrenia or autism13, 15, 17–22. While shortening or lengthening 
of TH-positive processes has not been reported in neuropsychiatric disease, both schizophrenia and autism have 
been associated with increased tyrosine hydroxylase staining in substantia nigra17 as well as abnormal dopamine 
and dopaminergic receptor levels in substantia nigra, striatum and prefrontal cortex17, 18. The offspring brain in 
the presented study also showed a loss of parvalbumin-containing cells in cortex and reticular nucleus, which has 
been linked to schizophrenia and ASD-like behaviours19, 20, and a reduction in astrocyte/neuron ratio. Previous 
studies of neurodevelopmental disease have suggested that astrocyte number may be differently affected in dif-
ferent regions of the brain23. As it is known that males show higher vulnerability to several neurodevelopmental 
disorders, including schizophrenia and autism63, it would be of future interest to investigate differences in ana-
tomical changes between male and female offspring brains following hypoxia and MitoQ-NP treatment and to 
establish if the treatment may be more beneficial in one sex over the other.
In addition to the neuroanatomical changes observed in offspring brains, changes in gene expression, among 
those genes involved in developmental processes, were detected within the fetal brain, in response to gestational 
hypoxia and MitoQ-NP treatment. Due to the lack of oxidative stress in the fetal brain following gestational 
hypoxia, the observed neuroanatomical and gene expression changes are less likely caused by a direct effect of 
the altered environmental oxygen and suggest an indirect effect of maternal hypoxia, potentially via the placenta. 
The observation that many of the morphological changes in the offspring brain were replicated ex vivo in cortical 
cultures exposed to culture medium conditioned by rat placenta or to fetal blood support the hypothesis that 
signalling from the placenta may play a role in neurodevelopment in utero. This is in keeping with previous find-
ings showing that cortical cultures exposed to culture media conditioned by placenta following ex vivo hypoxia/
reoxygenation, had shorter dendrites and altered levels of glutamate receptors43. The observation that the effects 
of fetal blood and conditioned media on neurons could be prevented by maternal treatment with MitoQ-NPs fur-
ther supports an involvement of the placenta, as MitoQ-NPs were localised and exerted their biological effects on 
oxidative stress in the placenta and not in the fetus. Moreover, the damaging effects of placental secretions were 
prevented six days after maternal injection with MitoQ-NPs.
The effects on cortical cultures were also replicated following controlled hypoxic exposure in a simple in vitro 
barrier model consisting of cytotrophoblast cells, which in the human face the fetal circulation. This suggests 
that oxidative stress in the placental barrier may mediate effects on the offspring brain, as other factors, such as 
mRNA
miRNA 
log2 FC
mRNA log2 
FC
Correlation 
coefficient
Adjusted p 
value
rno-miR-1
HSPA5 −0.92 0.71 −0.992 0.036
PDIA4 −0.92 0.64 −0.993 0.035
XBP1 −0.92 0.46 −0.992 0.035
RSPH1 −0.92 0.38 −0.994 0.035
rno-miR-17-5p RPL10L 0.81 −1.29 −0.990 0.040
rno-miR-20a + rno-
miR-20b-5p
ENG −0.61 0.53 −0.989 0.042
NOVA2 −0.61 0.36 −0.989 0.043
rno-miR-300-3p
HYOU1 −0.55 0.45 −1.000 0.035
MGLL −0.55 0.36 −0.990 0.036
VASP −0.55 0.33 −0.992 0.035
rno-miR-369-3p
FANCG −0.58 0.66 −0.990 0.038
FAM98A −0.58 0.25 −0.994 0.035
ENAH −0.58 0.21 −0.991 0.035
rno-miR-410
XBP1 −0.50 0.46 −0.993 0.035
RSPH1 −0.50 0.38 −0.992 0.035
rno-miR-451 EPHB4 −0.46 0.31 −0.988 0.049
rno-miR-499 NOVA2 −0.69 0.36 −0.991 0.036
Table 1. Significant correlations between miRNAs in fetal plasma and transcripts in fetal brain. miRNAs that 
were significantly altered in fetal plasma following gestational hypoxia were probed for negative correlation with 
mRNA that showed significantly changed levels in the fetal brain following the hypoxic insult. p values were 
adjusted for multiple comparisons using the Benjamini-Hochberg method.
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Figure 5. Effects of MitoQ-NPs on neurons. Effects of gestational hypoxia and MitoQ-NP treatment on 
neurons were examined in vitro by applying culture media conditioned by bilayered BeWo barriers or offspring 
placenta, or by applying fetal plasma to cortical cultures. Placental tissue and fetal plasma were collected 
from animals exposed to 6 d gestational normoxia, M(21%), or gestational hypoxia M(11%), in combination 
with maternal injection of either saline or MitoQ-NPs. Placental tissue was subsequently incubated ex vivo 
for 24 h under 8% oxygen conditions before collection of conditioned medium. BeWo barriers were cultured 
at 8% oxygen to mimic physiological oxygen conditions or at 2% oxygen followed by 8% oxygen to mimic 
hypoxia-rexoygenation (2–8%). (a–d) Dendrite lengths in vitro following exposure to BeWo conditioned 
medium (a; number of biological replicates from left to right: n = 25,25,15,15), placenta conditioned medium 
(b; n = 15,10,8,24) or plasma (c; n = 21,18,23,18) and in vivo (d) in somatosensory cortex (SSC; n = 8 different 
brains), combined somatosensory, auditory and retrosplenial cortex (CTX; n = 21,23,21,23) or thalamic 
reticular nucleus (TRN; n = 8). (e–i) Process lengths of tyrosine hydroxylase (TH)-positive neurons in 
vitro following exposure to BeWo conditioned medium (e; n = 25,25,15,15), placenta conditioned medium 
(f; n = 12,10,8,10), plasma (g; n = 21,27,19,19) or in neuron only-cultures following exposure to placenta 
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hormones that could be altered by the maternal hypoxia would not have been present in the in vitro model. We 
also observed a potential role of astrocytes in mediating the effects of gestational hypoxia and MitoQ-NP treat-
ment. It would therefore be of interest to test whether molecules in fetal blood which were altered by gestational 
hypoxia could have actions in the brain across a fetal blood-brain barrier via astrocytic end feet.
Analysis of factors in fetal blood and secreted from the placenta ex vivo, showed that the miRNA profile 
was significantly altered by gestational hypoxia and partially ‘normalised’ by maternal injection of MitoQ-NPs. 
miRNAs, small RNAs that function as post-transcriptional regulators, have been shown to play an important 
role in neurodevelopment56, 64, brain function65 and psychiatric diseases50, 56, 66. Various circulating miRNAs are 
being studied in patient blood samples in order to develop biomarkers for psychiatric disease66. Schizophrenia 
has generally been associated with an increase in the miRNA biogenesis machinery and with a broad upregula-
tion of cortical miRNAs67. Intriguingly, predicted targets of miRNAs significantly altered by gestational hypoxia 
in fetal blood and conditioned media were found to be enriched within CNVs associated with schizophrenia. 
Furthermore, a selection of miRNAs were negatively correlated with altered gene expression in the fetal brain. As 
an example, miR-17-5p was significantly upregulated following gestational hypoxia in both fetal blood and media 
conditioned by rat placenta; it was also significantly downregulated in response to maternal MitoQ-NP treat-
ment. miR-17-5p upregulation was associated with the downregulation of ribosomal protein L10-like (RPL10L), 
a ribosomal-like protein with unknown function, in the fetal brain. The miR-17 family of miRNAs plays a role in 
early neurodevelopment by regulating cell proliferation and differentiation in the cortex68. Moreover, an increase 
in miR-17-5p levels in the human prefrontal cortex has been associated with schizophrenia69, 70. The results 
indicate that miRNAs secreted by the placenta could play a role in mediating the effects of gestational hypoxia 
and drug treatment on the developing fetus and suggest a tentative link between secreted miRNAs and gene 
expression in the fetal brain. While RNA-loaded extracellular vesicles have been shown to be able to cross the 
blood-brain barrier into the brain57 and extracellular miRNAs have been shown to be functionally active after 
uptake in target cells in the brain71, the hypothesis that placenta-secreted miRNAs may regulate gene expression 
in the fetal brain remains to be tested.
The proteomic profiles in fetal blood and conditioned media were also altered in response to gestational 
hypoxia and MitoQ-NP treatment, respectively. Especially lipoprotein-related proteins were found to be differ-
entially abundant in foetal blood, which is of interest in view of the susceptibility of offspring to cardiovascular 
disease following gestational hypoxia45, 72. While an interplay between several different factors may be involved, 
the data strengthen the hypothesis of a mechanistic link between molecules secreted from the placenta, including 
miRNAs, and the effects of gestational hypoxia on the offspring brain. In some cases differential effects of hypoxia 
and drug treatment on the secretions in the fetal blood and in media conditioned by rat placenta were observed. A 
difference between the protein/miRNA profile of fetal blood and conditioned media is to be expected and this dif-
ference may reflect the complex interplay between molecules transported across the placenta, molecules secreted 
by the other fetal tissues, such as fetal liver, into fetal blood and molecules in the fetal blood that are regulated by 
the placenta. None of these factors would be present in the ex vivo preparation. In contrast, the protein/miRNA 
profile of culture medium conditioned by rat placenta would consist only of molecules released by the placenta, 
but in both directions, i.e. to the fetal and the maternal side.
The placenta has been shown to play a key role in fetal programming21, 27–32. The presented data suggest that 
treating the placenta with an antioxidant may prevent some changes in our models in response to hypoxia that 
are also considered to be important in the aetiology of human psychological disorders. Clinical trials with anti-
oxidants in human disease have generally been disappointing, perhaps because not enough antioxidant reaches 
the mitochondria73–77. MitoQ has the advantage of being recycled back to its active form after detoxification of 
a free radical78, 79. Moreover, in our rat model MitoQ-NPs were able to produce long-lasting effects following 
administration of a single controlled dose whilst only affecting the placenta and not the fetus. We propose a future 
possibility of treating the placenta, and not the fetus, in order to reduce the potential for disease in later life.
Methods
All animal procedures were conducted in accordance with the United Kingdom Animals Scientific Procedures 
Act (1986) following institutional ethical approval at the University of Birmingham and then carried out under 
Home Office project licence authority. Procedures conducted in Canada were approved by the University of 
Alberta Health Sciences Animal Policy and Welfare Committee, in accordance with the Canadian Council on 
Animal Care guidelines. All efforts were made to minimize any suffering and the number of animals used. All 
methods were performed in accordance with the relevant guidelines and regulation.
conditioned medium (h; n = 5,5,5,5). (i), TH+ process length in vivo in CTX (n = 121,108,123,98) and TRN 
(n = 63,56,59,43). (j–m) GluN1 receptor subunit staining intensity in vitro following exposure to BeWo 
conditioned medium (j; n = 15,15,8,9), placenta conditioned medium (k; n = 10,10,15,10) or plasma (l; 
n = 28,10,17,18), and in vivo (m) in SSC (n = 3), CTX (n = 3) and retrosplenial cortex (RSC; n = 3). (n–q) Ratio 
of astrocytes to neurons in vitro following exposure to BeWo conditioned medium (n; n = 15,15,18,12), placenta 
conditioned medium (o; n = 10) or plasma (p; n = 5) and in vivo (q) in hippocampus (HPC, n = 23,18,18,24), 
CTX (n = 70,66,72,77) and TRN (n = 32,40,44,28). (r) Representative images of neurons in TRN and SSC. 
Sections were stained for neuronal marker NeuN (red) and somato-dendritic marker neurofilament (green). 
Scale bar = 25 μm. (s) Density of parvalbumin (PV)-positive neurons in vivo in SSC (n = 21,42,42,33), CTX 
(n = 63,126,126,98) and TRN (n = 35,51,55,43). *p < 0.05, **p < 0.01, ***p < 0.001, Tukey’s test following 
ANOVA.
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Nanoparticles. The production of drug-loaded γ-PGA-Phe NPs80 is described in Supplemental Methods. 
Both in vitro and in vivo experiments used NPs carrying a final dose of 0.5 μM MitoQ.
Cell cultures. Bilayered cell barriers were prepared using BeWo cells, a choriocarcinoma cell line (gift from 
Dr Margaret Saunders, University of Bristol, UK)40, 41 grown on Transwell 0.4 μm pore polyester inserts (Corning, 
UK). Culture media for BeWo barriers consisted of Dubecco’s Modified Eagle’s Medium (DMEM) with F-12 
(Sigma-Aldrich) containing 10% FBS (Thermo Fisher Scientific) and 2 mM L-glutamine (Sigma-Aldrich). Cell 
lines were routinely tested for mycoplasma contamination. Integrity of cell barriers was tested by applying fluo-
rescein isothiocyanate-conjugated BSA (FITC-BSA; Sigma-Aldrich) at a final concentration of 100 μg/mL to the 
top of cell barriers in Transwell inserts and an equal concentration of non-conjugated BSA to the medium below 
barriers. Fluorescence intensity was measured 1 h later in the media below the barriers and in the insert.
Cortical cultures were prepared from dissociated rat E18 cortical tissue and grown on glass coverslips as 
described previously43, in Gibco Neurobasal media with 1x Gibco B-27 Supplement, 1x antibiotic-antimycotic 
(all Thermo Fisher Scientific) and 2 mM L-glutamine. To produce neuron-only cultures, 40 μM 
5-fluoro-2-deoxyuridine was added to each well at 5 days in vitro. Astrocyte-only cultures were prepared by grow-
ing cortical cultures in DMEM with 10% FBS, 2 mM L-glutamine and 1x antibiotic-antimycotic. Cultures were 
accepted as astrocyte-only if neuron number was zero in three representative coverslips. The effect of glutamate 
Figure 6. Roles of astrocytes and glutamate signalling in mediating the effects of maternal hypoxia and 
MitoQ-NPs on neurodevelopment. Mixed cortical cultures (a,d,g) or neuron-only cortical cultures (b,e,h) were 
incubated with rat placenta conditioned media. The latter were also incubated with medium conditioned by 
astrocytes which had previously been exposed to rat placenta conditioned media (c,f,i). Placentas were collected 
from pregnant rats that had been exposed to normoxia, M(21%), or hypoxia, M(11%), in combination with an 
injection of saline or MitoQ-NP. This was followed by incubation of the placenta in culture medium for 24 h 
ex vivo at 8% oxygen. To some of the cortical cultures NMDA receptor antagonist MK-801 was added with the 
conditioned medium. (a–c) Dendrite lengths of neurons (number of biological replicates from left to right: a, 
n = 5; b, n = 5, 4, 5, 3, 3, 3; c, n = 5; d, n = 10). (d–f) Dendrite lengths of tyrosine hydroxylase (TH)-positive 
neurons (n = 5, 3, 5, 3, 3, 3). (g–i) Staining intensity of GluN1 receptor subunits (e, n = 7, 9, 5, 7; f, n = 3; g, 
n = 5; h, n = 12, 10, 10, 11, 25, 10). Significant differences determined using Tukey’s test following ANOVA 
(*p < 0.05, **p < 0.01, ***p < 0.001).
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was investigated by adding MK-801, a NMDA receptor antagonist, at a concentration of 10 μM to each well and 
incubating for 4 h before exposure of the cells to conditioned media. Exposures of cortical cultures were per-
formed at a minimum in triplicate for condition medium from each of 3 placenta (one from each dam), creating a 
minimum of 9 data points for each condition. At least three different sets of cortical cultures were tested.
Conditioned media. Conditioned tissue culture media were prepared using bilayered barriers described 
above or using rat placentas isolated from the in vivo experiment (see below). Barriers were grown and tissues 
were incubated at 21%, 8% or 2% oxygen in a SCI-tive hypoxia chamber (Baker Ruskinn, USA). This was followed 
by a 24 h exposure period, at the start of which the media under the barriers or around the tissue was replaced. 
Some wells were additionally exposed to NPs above the barrier. The media was then conditioned by the explant 
or barrier for 24 h at the same or altered oxygenation. Conditioned media were applied to embryonic cortex for 
6 days from day 12 in vitro to test their effects on cell number, dendrite length, tyrosine hydroxylase positive cell 
processes and glutamate receptors as previously described40, 41. Cortical cultures were also exposed to condi-
tioned medium collected from astrocyte-only cultures that had been exposed for 24 h to rat placenta-conditioned 
medium. Potential leakage of MitoQ from barriers or placenta was measured in the conditioned medium using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS)81.
Immunocytochemistry. Cortical cultures were fixed in supercold methanol (−20 °C), washed with PBS and 
blocked with 5% BSA, 5% NGS in PBS for 30 min. They were incubated with primary antibodies against MAP2 
(1:2000, #188004; Synaptic Systems, Germany), GFAP (1:1000, #3670; Cell Signalling Technology), tyrosine hydrox-
ylase (1:500, ab112; abcam) and GluN1 (1:500, ab9864; Merck Millipore), overnight at 4 °C. Sections were stained 
with secondary antibodies Alexa Fluor 488 anti-rabbit IgG, Alexa Fluor 488 anti-mouse IgG or Alexa Fluor 488 
anti-guinea pig IgG (all Thermo Fisher Scientific, diluted 1:500) for 2 h at room temperature under minimal light 
conditions, washed with PBS and mounted in DAPI mounting media. Five images per coverslip were taken on a 
confocal microscope (SP2-AOBS, Leica). Analysis of the slides was performed with the experimenter blind to the 
experimental group. Dendrite lengths were measured using ImageJ. For receptors images were taken at x64 (with 
oil) on a fluorescence microscope (Leica SP5II) after excitation at 488 nm. Using ImageJ, images were converted to 
RGB files then measurements were taken of the mean grey value of each image providing an average of the relative 
intensity of the staining. Measurements were verified by cell counts based on DAPI staining. Background levels of 
fluorescence were ascertained in the absence of cells, primary antibody and/or secondary antibody.
In vivo experiments. Three-month-old female Sprague-Dawley rats (Charles River, Wilmington, MA) were 
maintained on ad libitum standard rat chow and tap water in a 12:12-h light-dark cycle and acclimatized before 
breeding. Day 0 of pregnancy was determined by sperm in a vaginal smear. On gestational day (GD) 15 of preg-
nancy the rats were injected intravenously with saline (vehicle control) or 125 μM MitoQ-NPs and exposed for 
the next 6 days to 21% or 11% oxygen in an A-Chamber (BioSpherix, USA)44. Some rats were sacrificed at GD20. 
EDTA plasma collected from fetuses by decapitation was pooled per litter and flash frozen; placenta, maternal 
and fetal tissues were collected fresh, flash-frozen or fixed in formal saline. Other rats were allowed to give birth in 
normal oxygen conditions. Birth-weights were measured and offspring brains examined at postnatal day (P) 30.
Statistical tests were not used to predetermine sample size. Experimental groups were allocated according to 
a preassigned schedule, depending on the order in which successful pregnancy was established. From each litter 
two males and two females were randomly selected for examination at P30. For subsequent immunohistochem-
istry analysis of rat tissue, the experimenter was blinded to group allocation.
Localisation of NPs. Pregnant rats were injected with 125 μM NPs conjugated with Alexa Fluor 488 and 
culled at GD16 to collect flash-frozen fetal, maternal and placental tissue. Sagittal sections of placental labyrinth 
and junctional zone, sections of fetal and maternal cortex and liver were produced using a cryostat and viewed 
with confocal microscopy for the localisation of fluorescent NPs.
Analysis of placental, fetal and maternal tissues. Fixed placentas were processed for paraffin wax his-
tology. Sections were cut at 3 μm and stained with haematoxylin and eosin and at 2 μm for avidin-biotin immu-
nocytochemistry for CD34 (ab81289; abcam, UK) using a full automated Bond3 immunostaining machine with 
bond polymer refined detection (Leica) to ensure the same immunostaining method was applied to all sections. 
Images were captured on a fluorescent microscope (Leica SP5II) and analysed with ImageJ software. Numbers of 
biological replicates are given in figure legends. For measurements pertaining to placenta vasculature, values for 
each biological replicate are averages of technical replicates taken from multiple fields of view.
Levels of reactive oxygen species (ROS) were measured in fetal, maternal and placental tissues using the 
2′,7′-dichlorofluorescein diacetate (DCFDA) assay. Sagittal sections (10 μm) were cut on the cryostat and exposed 
to 20 μM DCFDA solution in HBSS at 37 °C in a humidifying chamber. After counter-staining with DAPI, slides 
were immediately imaged using a confocal microscope (excitation and emission wavelengths of 495 nm and 
529 nm, respectively). Using Image-Pro Premier 9.2 (Media Cybernetics, USA), fluorescence levels of DCF, the 
product of DCFDA deacetylation by cellular esterases and oxidisation by ROS, were quantified in labyrinth and 
junctional zone of the placenta, maternal and fetal liver, cortex and cerebellum.
Analysis of conditioned media and plasma. BMP4, 6 and 9 were measured in conditioned media using 
a cell based assay82. Amino acids were measured as previously described43.
Total RNA was extracted from 200 μl conditioned media or 100 μl fetal plasma using the miRNeasy Mini Kit 
and the miRNeasy Serum/Plasma Kit (Qiagen, Germany). Small RNA and miRNA levels were measured using the 
Small RNA Kit on the 2100 Bioanalyzer (Agilent Technologies) at the University of Bristol Genomics Facility. Levels 
of individual miRNAs were analysed using the nCounter Rat v1 miRNA Expression Assay or the nCounter Human 
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v2 miRNA Expression Assay (NanoString Technologies, USA), which detects 423 or 800 different species-specific 
miRNAs, respectively. Briefly, 3 μl of each undiluted sample were hybridised with barcoded probes and immobilised 
on an nCounter Cartridge. Barcode signals were counted using the nCounter Digital Analyzer.
Proteomic analysis was performed by the University of Bristol Proteomics Facility (see Supplementary 
Methods for details). Briefly, samples were depleted of rat albumin, digested with trypsin and labelled with 
Tandem Mass Tag (TMT) 10Plex reagents (Thermo Fisher Scientific). The labelled samples were fractionated by 
high pH reversed-phase chromatography followed by nano LC-MS/MS. The raw data files were processed and 
quantified using Proteome Discoverer software v1.4 (Thermo Fisher Scientific) and searched against the UniProt 
Rat database using the SEQUEST algorithm. All peptide data was filtered to satisfy a false discovery rate of 5%.
RNA sequencing. RNA was extracted from 50 mg of fetal frontal cortex tissue at GD20 using the RNeasy 
Mini kit (Qiagen). RNA quality and integrity was measured on the 2100 Bioanalyzer. mRNA sequencing was 
performed by Edinburgh Genomics. Libraries were prepared from total RNA samples using the Illumina TruSeq 
stranded mRNA Sample Preparation Kit. Briefly the polyA RNA from 1 ug of total RNA was captured onto Oligo 
d(T) beads, before fragmentation and elution of the polyA RNA. The RNA was reverse transcribed using random 
primers and the resulting cDNA was double stranded. The cDNAs were ligated with adapters containing unique 
barcodes for each sample. Libraries were then assessed for size by electrophoresis and quantified by qPCR. The 
libraries were sequenced by 75 bases paired-end sequencing across two lanes of an Illumina HiSeq 4000. This level 
of sequencing produced greater than 34 million paired reads per sample. The FASTQ files were generated using 
the standard Illumina pipeline for bcl2fastq.
Bioinformatic analyses. Differential expression analysis of NanoString miRNA data is detailed in 
Supplementary Methods. TargetScanHuman v7.083 was used to create a list of potential (human-equivalent) tar-
gets of the significant miRNAs (Total Context Score < −0.2). Predicted target genes were analysed for pathway 
enrichment of CNVs associated with schizophrenia, as described by Pocklington et al.58. The analysis was applied 
to the combined ISC + MGS + CLOZUK dataset, comprising a total of 11,355 cases and 16,416 controls. The 
analyses are based on large, rare CNVs (>100 kb, frequency <1%), as these are both the most robustly called and 
most enriched in people with schizophrenia. The primary analysis was performed on all CNVs, with secondary 
analyses performed for deletions and duplications separately. A further analysis was performed conditioning 
on the ‘minimal’ gene sets previously shown to capture CNS-related gene set enrichment in this CNV dataset58.
Peptide spectra from the proteomics data set were analysed using moderated t-statistics from the empirical 
Bayes method to calculate differential protein abundance. Modified scripts, published by Kammers et al.84 and 
based on the limma package85, were used.
We used Tophat86 to align RNA sequencing reads to the rat reference genome Rnor_6.0 (GenBank Assembly 
ID GCA_000001895.4), and HTSeq87 to generate read counts from the resulting BAM files. Out of 672 million 
paired-end reads, nearly 557 million (82.8%) concordant pairs mapped to unique locations in the Rn6 version 
of the genome. Genes were analysed for differential expression and differentially expressed genes were further 
analysed for interactions with the miRNA data sets (see Supplementary Methods).
Differentially abundant proteins, differentially expressed genes and predicted targets of differentially secreted 
miRNAs were analysed for enrichment of biological processes, cellular compartments and tissues using the 
GO-slim feature in PANTHER 11.088, 89 and the GO Direct and UP_TISSUE features in DAVID 6.890, 91. Venn 
diagrams were produced using Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
Data availability. Raw and processed data files generated from NanoString and RNA sequencing analyses 
have been deposited in NCBI’s Gene Expression Omnibus92 and are accessible through GEO Series accession 
number GSE86410. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository93 with the dataset identifiers PXD004955 and PXD004956 for fetal plasma and condi-
tioned medium, respectively.
Immunohistochemistry of P30 brains. At P30 rats were anaesthetised with 4% isoflurane and perfused 
with 4% PFA. Brains were post-fixed in 4% PFA, placed in 30% sucrose until sunk and embedded in OCT. Three 
brains per condition were randomly selected, one from each litter. 12-μm cryostat sections were produced and 
mounted as contiguous triplicates. Brain sections were exposed to cold methanol at −20 °C for 10 min for fix-
ation. For GluN1 staining, sections were fixed in 2% PFA, followed by permeabilisation in 0.3% Triton X-100 
in PBS for 15 min. All slides were washed in PBS after every incubation step. Slides were blocked with 5% goat 
serum (Sigma-Aldrich), 0.3% Triton X-100 in PBS for 2 h at 4 °C, followed by an overnight incubation (or 48 h 
incubation for GluN1 staining) at 4 °C in primary antibody in PBS with 1% BSA, 0.3% Triton X-100. Antibodies 
used were raised against MAP2 (1:500, ab32454; abcam), NeuN (1:1000, ab177487; abcam), neurofilament (1:500, 
ab24575; abcam), GFAP (1:500, #3670; Cell Signaling Technology), parvalbumin (1:500, ab11427; abcam), tyros-
ine hydroxylase (1:500, ab112; abcam) and GluN1 (1:200, MAB1570, Merck Millipore). Slides were incubated 
with secondary antibody Alexa Fluor 555 anti-rabbit IgG, Alexa Fluor 488 anti-mouse IgG or Alexa Fluor 568 
anti-mouse IgG (Thermo Fisher Scientific) at 1:500 for 2 h at 4 °C. Vectashield Mounting Medium with DAPI 
(Vector Laboratories, USA) was used to mount coverslips. Coronal sections were chosen to show thalamic retic-
ular nucleus, primary somatosensory, primary auditory and retrosplenial granular cortex94. Damaged sections, 
due to problems with freezing or storage of the samples, were excluded from analysis after visual confirmation. 
Analysis of brain sections was done with the experimenter blind to the in vivo exposure. For each site, in each 
brain, a minimum of 5 fields of view were examined for each of 3 sections in both hemispheres using a LASX 
(Leica) widefield microscope or a SP5II (Leica) confocal microscope at x40 magnification using oil. This resulted 
in a minimum of 30 fields of view being analysed for each site. The analysis of the intensity of the IHC staining 
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of GluN1 was determined using a similar approach to that used previously95. Briefly, nine sections per condition 
were imaged and 10–12 images were collected for every brain region per case and using the same microscopy set-
tings of intensity and magnification to allow for a meaningful comparison. Photos were sorted and converted to 
greyscale then the total pixel number was determined using a corrected macro for ImageJ. The total pixel number 
was subsequently subtracted from the background.
Statistics. Data are presented as means ± s.e.m. For all statistical comparisons, variances were similar in 
magnitude between the compared groups. As indicated in the figure legends, one-way or two-way ANOVA was 
performed in Prism 6.0 (GraphPad, USA) or SPSS 21.0 (IBM Corp., USA) with post-hoc analysis using Bonferroni 
correction or Tukey’s test for multiple comparisons. Two-way ANOVA was used to test for main effects of drug 
and of oxygen conditions and for interaction effects. For GluN1 staining intensity analysis, normality of data dis-
tribution was tested using the D’Agostino-Omnibus normality test in Prism 6.0 (p > 0.05) and parametric testing 
was applied to test for differences of means between groups using multiple unpaired, two-sided Student’s t-test 
post-hoc testing adjusted for multiple comparisons using Bonferroni correction.
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